Uniform surface modification of 3D Bioglass®-based scaffolds with mesoporous silica particles (McM-41) for enhancing drug delivery capability

被引:21
作者
Boccardi, Elena [1 ]
Philippart, Anahi [1 ]
Juhasz-Bortuzzo, Judith A. [1 ]
Beltran, Ana M. [2 ,4 ]
Novajra, Giorgia [3 ]
Vitale-Brovarone, Chiara [3 ]
Spiecker, Erdmann [2 ]
Boccaccini, Aldo R. [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Inst Biomat, Dept Mat Sci & Engn, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Dept Mat Sci & Engn, Inst Micro & Nanostruct Res, Ctr Nanoanal & Electron Microscopy CENEM, Erlangen, Germany
[3] Politecn Torino, Inst Mat Phys & Engn, Appl Sci & Technol Dept, Turin, Italy
[4] Univ Seville, CSIC, ICMS, Seville, Spain
关键词
ordered mesoporosity; silica; MCM-41; bioactive glass; scaffolds; drug release; ibuprofen;
D O I
10.3389/fbioe.2015.00177
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
The design and characterization of a new family of multifunctional scaffolds based on bioactive glass (BG) of 45S5 composition for bone tissue engineering and drug delivery applications are presented. These BG-based scaffolds are developed via a replication method of polyurethane packaging foam. In order to increase the therapeutic functionality, the scaffolds were coated with mesoporous silica particles (MCM-41), which act as an in situ drug delivery system. These sub-micron spheres are characterized by large surface area and pore volume with a narrow pore diameter distribution. The solution used for the synthesis of the silica mesoporous particles was designed to obtain a high-ordered mesoporous structure and spherical shape - both are key factors for achieving the desired controlled drug release. The MCM-41 particles were synthesized directly inside the BG-based scaffolds, and the drug-release capability of this combined system was evaluated. Moreover, the effect of MCM-41 particle coating on the bioactivity of the BG-based scaffolds was assessed. The results indicate that it is possible to obtain a multifunctional scaffold system characterized by high and interconnected porosity, high bioactivity, and sustained drug delivery capability.
引用
收藏
页数:12
相关论文
共 32 条
[1]
Beck J. S., 1992, U.S. Patent, Patent No. [5108725, 5 108 725]
[2]
Characterisation of Bioglass based foams developed via replication of natural marine sponges [J].
Boccardi, E. ;
Philippart, A. ;
Juhasz-Bortuzzo, J. A. ;
Novajra, G. ;
Vitale-Brovarone, C. ;
Boccaccini, A. R. .
ADVANCES IN APPLIED CERAMICS, 2015, 114 :S56-S62
[3]
Dilute solution routes to various controllable morphologies of MCM-41 silica with a basic medium [J].
Cai, Q ;
Luo, ZS ;
Pang, WQ ;
Fan, YW ;
Chen, XH ;
Cui, FZ .
CHEMISTRY OF MATERIALS, 2001, 13 (02) :258-263
[4]
Effect of pH and ionic strength on the reactivity of Bioglass® 45S5 [J].
Cerruti, M ;
Greenspan, D ;
Powers, K .
BIOMATERIALS, 2005, 26 (14) :1665-1674
[5]
45S5 Bioglass®-derived glass-ceramic scaffolds for bone tissue engineering [J].
Chen, QZZ ;
Thompson, ID ;
Boccaccini, AR .
BIOMATERIALS, 2006, 27 (11) :2414-2425
[6]
Mechanised nanoparticles for drug delivery [J].
Coti, Karla K. ;
Belowich, Matthew E. ;
Liong, Monty ;
Ambrogio, Michael W. ;
Lau, Yuen A. ;
Khatib, Hussam A. ;
Zink, Jeffrey I. ;
Khashab, Niveen M. ;
Stoddart, J. Fraser .
NANOSCALE, 2009, 1 (01) :16-39
[7]
The synthesis of micrometer- and submicrometer-size spheres of ordered mesoporous oxide MCM-41 [J].
Grun, M ;
Lauer, I ;
Unger, KK .
ADVANCED MATERIALS, 1997, 9 (03) :254-&
[8]
Novel pathways for the preparation of mesoporous MCM-41 materials:: control of porosity and morphology [J].
Grün, M ;
Unger, KK ;
Matsumoto, A ;
Tsutsumi, K .
MICROPOROUS AND MESOPOROUS MATERIALS, 1999, 27 (2-3) :207-216
[9]
Hench L. L., 2015, BIOMEDICAL GLASSES, V1, P1, DOI [DOI 10.1515/BGLASS-2015-0001, 10.1515/bglass-2015-0001]
[10]
How useful is SBF in predicting in vivo bone bioactivity? [J].
Kokubo, T ;
Takadama, H .
BIOMATERIALS, 2006, 27 (15) :2907-2915